show progress pipelin approv skyrizi
upgrad rate buy maintain tp
tp base forward price-to-earnings
multipl adjust ep
provid upsid potenti
tp unchang rate chang buy due
increas upsid potenti upsid potenti
increas due fall stock price
base previou report
maintain recommend expect revenu
earn expect top-lin revenu
grow
estim base follow factor declin
humira revenu market approv
new product skyrizi new product launch
studi rova halt
abbvi revenu declin
increas oper revenu declin due
decreas humira intern revenu due
biosimilar competit howev humira revenu
 increas face
biosimilar competit
announc fda approv skyrizi
risankizumab-rzaa inhibitor
treatment moder sever plaqu psoriasi adult
candid system therapi phototherapi
compani nameabbvi inctickerabbvstock ratingbuyupgradeindustri viewoverweightpositivepric jun week week volum volum mrq n/aforward ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth abbvi inc june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
expect secur rapid broad formulari
coverag skyrizi commerci
access end juli access metric
achiev recent launch psoriasi
skyrizi repres signific long-term opportun
multi-billion dollar peak sale potenti
revenu guidanc includ
skyrizi sale predominantli occur
issu ep guidanc
guidanc reflect non-
cash charg conting consider relat
approv skyrizi plan commun
earn call
global imbruvica revenu increas
result continu penetr imbruvica
patient cll well favor price
net revenu venclexta increas
due market share gain
follow addit regulatori approv venclexta
treatment patient relapsed/refractori cll
aml
current price-to-earnings lower
due declin stock price price-to-earnings trail
past averag price-to-earnings expect forward
price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per old n/a last split date n/atrad inform inc june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research develop sell gener administr sg oper profit interest incom interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli abbvi inc june
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbvi inc june
oper cash flow increas compar due
improv result oper improv oper earn time work
capit cash flow oper cash flow also reflect contribut defin benefit plan
net cash use invest activ compar
includ net sale matur invest secur total payment made
acquisit invest capit expenditur
net cash use financ activ compar
includ repay term loan credit agreement schedul
matur june
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end abbvi inc june
inc first quarter revenu declin due decreas humira
compar
total revenu decreas compar
revenu increas oper due revenu
growth relat imbruvica venclexta well continu
strength humira revenu off-set intern humira biosimilar
compar
favor impact
expir
total revenu increas
compar total intern revenu decreas
compar
cog decreas compar
adjust cog
gross profit increas compar
gross margin increas compar
favor impact expir humira royalti
sg expens decreas compar
sg expens unfavor impact
restructur charg adjust sg expens
sg expens revenu decreas compar
favor impact lower litig reserv
charg decreas well lower administr cost
 expens increas compar
due restructur charg increas fund support
abbvi emerg earli mid-stag pipelin asset adjust
expens expens revenu
rel flat acquir in-process
compar
oper incom increas compar
oper margin compar
net interest expens increas compar
increas due unfavor impact higher
interest rate debt oblig higher averag outstand
expens compar incom
incom expens net includ charg
relat chang fair valu conting consider liabil
compar benefit
effect tax rate increas adjust tax rate
increas effect tax rate due benefici
impact time provis tax cut job act act relat
earn certain foreign subsidiari prior year effect tax rate
also reflect favor resolut variou tax posit lower
excess tax benefit stock-bas compens compar prior
net incom decreas compar
ep compar
adjust ep increas compar
increas
compar
gaap ep
compar
abbvi product focus treat condit chronic
autoimmun diseas rheumatolog gastroenterolog dermatolog
oncolog includ blood cancer virolog includ hepat hcv
human immunodefici viru hiv neurolog disord
parkinson diseas metabol diseas includ thyroid diseas
complic associ cystic fibrosi well seriou health
total revenu humira decreas
compar decreas result
direct biosimilar competit certain intern market partial
off-set market growth across therapeut categori
total revenu increas
compar due market growth across
total intern revenu decreas
compar decreas due direct
biosimilar competit certain intern market follow
expir european union composit matter patent
adalimumab octob
biosimilar competit humira expect unit state
continu pursu strategi intend
differenti humira compet product add
sustain humira
total revenu
humira decreas
compar
revenu decreas
compar
imbruvica venclexta
total revenu
imbruvica increas
compar
total revenu imbruvica increas
compar increas due continu
penetr imbruvica patient cll well favor
total revenu increas
compar total collabor revenu increas
compar
total revenu
mavyret decreas
compar
total revenu venclexta increas
compar increas due
market share gain follow addit regulatori approv
venclexta treatment patient relapsed/refractori cll
aml
total revenu increas compar
total intern revenu increas
compar
total revenu mavyret decreas
compar decreas result
declin market price certain intern geographi
partial off-set posit share dynam intern
total revenu
viekira decreas
compar
total revenu increas
compar total intern revenu decreas
compar
total revenu viekira decreas
compar total revenu declin
compar total intern
revenu declin compar
total revenu
kaletra increas
compar
total revenu creon increas
compar total revenu increas due
continu market growth higher market share creon maintain
market leadership pancreat enzym market
total revenu kaletra increas
compar total revenu increas
compar total
intern revenu increas
compar
total revenu synagi decreas
compar
total revenu
lupron increas
compar
total revenu androgel decreas
compar
total revenu synthroid increas
total revenu
compar
compar
total revenu lupron increas
compar total revenu
increas compar
total intern revenu decreas
compar
total revenu duodopa increas
compar due increas market
total revenu increas
compar total intern revenu increas
compar
total revenu sevofluran decreas
compar total revenu
declin compar total
intern revenu declin
compar
regulatori approv
skyrizi
treatment adult
patient moder
sever plaqu
psoriasi
candid system
therapi phototherapi
announc regulatori approv skyrizi treatment
adult patient moder sever plaqu psoriasi candid
system therapi phototherapi approv fda
japanes ministri labour welfar base result
four pivot phase studi immvent immhanc
evalu patient moder sever plaqu psoriasi
european medicin agenc committe medicin product
human use adopt posit opinion skyrizi treatment
moder sever plaqu psoriasi adult patient candid
system therapi skyrizi part collabor boehring
ingelheim lead develop
american academi dermatolog aad annual meet
present data abstract includ oral present poster
present long-term data multipl studi investig skyrizi
treatment plaqu psoriasi present includ first integr
efficaci analys highlight respons time across variou
abbvi present month skyrizi safeti data indic advers
event low similar compar group data show
psoriasi patient achiev significantli higher pasi respons rate
switch skyrizi versu remain adalimumab also
present result phase upadacitinib atop dermat studi well
data humira adalimumab multipl psoriat diseas
announc fda accept prioriti review new drug
applic nda upadacitinib treatment adult patient
moder sever rheumatoid arthriti nda support data
global upadacitinib select phase rheumatoid arthriti program
evalu patient moder sever rheumatoid
arthriti across five six phase studi anticip regulatori
decis
announc
fda approv
use imbruvica
ibrutinib
combin
obinutuzumab adult
patient previous
announc fda approv use imbruvica ibrutinib
combin obinutuzumab adult patient previous
cll/sll mileston mark fda approv imbruvica six
differ diseas area sinc expand use imbruvica
alreadi administ singl agent combin
bendamustin rituximab adult cll/sll patient
fda approv base result phase studi
show combin imbruvica plu obinutuzumab significantli
improv progression-fre surviv compar chlorambucil plu
obinutuzumab previous untreat cll/sll patient year
older less year old coexist condit
fda also updat imbruvica label includ addit long-term
efficaci follow-up data phase reson studi
support use singl agent cll/sll imbruvica jointli develop
commerci janssen biotech inc
announc fda grant fifth breakthrough therapi
design venclexta venetoclax use combin
obinutuzumab fix durat investig combin untreat
adult patient cll design coincid complet
supplement new drug applic snda submiss fda approv
previously-untr cll patient
snda grant prioriti review fda snda
venclexta obinutuzumab combin base data phase
trial review fda real-tim oncolog
review pilot program venetoclax develop roch
jointli commerci genentech member roch
group outsid
voyag
compani focus
treatment sever
provid updat venclexta multipl myeloma program
announc fda place partial clinic hold clinic trial
evalu venclexta investig treatment multipl
myeloma partial clinic hold follow review data on-going
phase bellini trial studi relapsed/refractori multipl myeloma
higher proport death observ venclexta arm
compar control arm trial action impact
approv indic venclexta cll acut myeloid
leukemia limit investig clinic trial multipl myeloma
addit analys on-going data publish peer-review
journal and/or present futur medic meet
announc strateg partnership teneobio biotechnolog
compani develop new class biolog treatment cancer
autoimmun infecti diseas agreement
teneobio develop commerci b-cell matur
antigen bcma -target immunotherapeut potenti treatment
platform expand develop potenti life-chang treatment
patient
announc strateg collabor
clinical-stag gene therapi compani focus develop life-chang
treatment sever neurolog diseas voyag therapeut
transact expand collabor effort vector antibodi target
patholog speci alpha-synuclein potenti treatment
parkinson diseas diseas character abnorm
accumul misfold alpha-synuclein protein
voyag vector antibodi platform approach aim improv
deliveri suffici quantiti antibodi across blood-brain barrier
deliv gene encod product therapeut antibodi
collabor broaden neurosci research platform
expand develop potenti life-chang treatment patient
rais
rang
repres
growth
exclud non-
cash amort
specifi item
issu ep guidanc
guidanc reflect non-cash charg conting
consider relat approv skyrizi plan
commun earn call
rais previous announc adjust ep guidanc rang
repres growth mid-point
abbvi adjust dilut ep guidanc exclud per share
intang asset amort expens non-cash charg conting
consider adjust specifi item
expect adjust ep exclud
non-cash amort specifi item guidanc
exclud non-cash charg conting consider relat
approv skyrizi anticip adjust revenu
forecast adjust oper margin ratio compar first
quarter result anticip higher spend second half year
relat new product launch also also expect adjust tax rate
line full year guidanc rate
abbvi revenu declin increas
oper revenu declin due decreas humira
revenu intern market due biosimilar
competit humira revenu increas
ep compar
adjust ep increas compar
global net revenu hematolog oncolog portfolio increas
oper basi global
imbruvica revenu increas result continu
penetr imbruvica patient cll well favor price
net revenu venclexta increas
due market share gain follow addit regulatori approv
venclexta treatment patient relapsed/refractori cll aml
global hcv net revenu decreas oper
basi total revenu mavyret decreas
compar decreas result declin
market price certain intern geographi partial off-set
posit share dynam intern market
announc food drug administr fda approv
skyrizi risankizumab-rzaa inhibitor
treatment moder sever plaqu psoriasi adult candid
system therapi phototherapi show tremend
advanc pipelin approv skyrizi expect
potenti blockbust futur
declin due decreas
humira revenu
intern
market due
biosimilar competit
advanc
pipelin
approv skyrizi
expect
potenti blockbust
futur
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas ttm basi compar
oper margin increas ttm basi compar
net margin ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbvi inc june
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale abbvi inc june
invest flow
sale
mrqfinanci mrqyoy growth revenu growthoper incom growthep mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale abbvi inc june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item abbvi inc june
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free abbvi inc june
current price-to-earnings lower due declin stock price price-to-earnings
trail past averag price-to-earnings
price-to-earnings fallen sinc due fall stock price result failur drug rova
acquir price-to-earnings surg januari due rise
stock price expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluecapit research global vanguard group inc geod capit manag northern trust orbi gray capit world top mutual fund holdersholdersharesd report outvalueinvest compani vanguard total stock market capit incom builder vanguard capit world growth incom amcap growth fund america spdr etf american mutual fund vanguard institut fund-institut competit
developmentsnew two-year data world congress dermatolog show skyrizi risankizumab maintain complet skin clearancejun announc new result show signific number patient treat skyrizi risankizumab experienc complet skin clearanc week studi week patient achiev static physician global assess spga score clear almost clear spga re-random continu treatment skyrizi withdraw week continu treatment skyrizi patient achiev spga score clear spga improv psoriasi area sever index pasi respect compar patient re-random withdraw present data venetoclax chemotherapy-fre combin regimen patient previous untreat chronic lymphocyt leukemiajun present data trial first random clinic trial examin stop oral-bas chemotherapy-fre combin month previous untreat patient cll coexist medic condit result demonstr venetoclax plu obinutuzumab prolong progression-fre surviv achiev higher rate complet respons minim residu diseas mrd -neg compar commonli use standard care obinutuzumab plu chlorambucil resolv humira adalimumab patent litig boehring ingelheimmay announc resolv humira adalimumab litig boehring ingelheim bi term resolut grant bi non-exclus licens humira-rel intellectu properti inth unit state licens bi beginonjuli bi pay royalti licens humira patent acknowledg valid enforc licens patent make payment form bi expand immunolog portfolio fda approv skyrizi risankizumab-rzaa moder sever plaqu announc food drug administr fda approv skyrizi risankizumab-rzaa inhibitor treatment moder sever plaqu psoriasi adult candid system therapi clinic trial skyrizi produc high rate durabl skin clearanc peopl percent treat skyrizi achiev percent skin clearanc pasi one year major percent achiev complet skin clearanc pasi inc june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast
lower
compar
forward price-to-earnings
lower
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonabbvindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
price target summarycrispidea capit maintainsunderperformunderperformrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext abbvi inc june
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil quarter surg april due approv
howev stock declin result declin period
stock price show declin trend past due studi drug halt
rang stock
stock price show upward trend till januari later declin year due
uncertainti drug acquir
stock given return past due growth busi
abbvi revenu quarter declin due declin humira revenu
intern market due biosimilar competit upgrad rate buy
due decreas stock price quarter led increas upsid potenti
howev maintain expect growth revenu growth revenu
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
